BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 27693123)

  • 1. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
    Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
    Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and potential predictors of thromboembolic events in epithelial ovarian carcinoma patients during perioperative period.
    Zhou Q; Zhu C; Shen Z; Zhang T; Li M; Zhu J; Qin J; Xie Y; Zhang W; Chen R; Wang G; Qian L; Wu D; Nashan B; Zhou Y
    Eur J Surg Oncol; 2020 May; 46(5):855-861. PubMed ID: 32001042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laparoscopic staging for apparent stage I epithelial ovarian cancer.
    Melamed A; Keating NL; Clemmer JT; Bregar AJ; Wright JD; Boruta DM; Schorge JO; Del Carmen MG; Rauh-Hain JA
    Am J Obstet Gynecol; 2017 Jan; 216(1):50.e1-50.e12. PubMed ID: 27567562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of residual tumor locations in advanced ovarian cancer patients after incomplete primary cytoreduction.
    Grabowskil JP; Mardas M; Markowska A; Markowska J
    Eur J Gynaecol Oncol; 2015; 36(3):274-7. PubMed ID: 26189252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study.
    Gueli Alletti S; Petrillo M; Vizzielli G; Bottoni C; Nardelli F; Costantini B; Quagliozzi L; Gallotta V; Scambia G; Fagotti A
    Gynecol Oncol; 2016 Dec; 143(3):516-520. PubMed ID: 27769526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
    Eriksson AGZ; Graul A; Yu MC; Halko A; Chi DS; Zivanovic O; Gardner GJ; Sonoda Y; Barakat RR; Abu-Rustum NR; Leitao MM
    Gynecol Oncol; 2017 Aug; 146(2):263-267. PubMed ID: 28527673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
    Chan JK; Java JJ; Fuh K; Monk BJ; Kapp DS; Herzog T; Bell J; Young R
    Gynecol Oncol; 2016 Dec; 143(3):490-495. PubMed ID: 27771168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laparoscopic Versus Laparotomic Surgical Staging for Early-Stage Ovarian Cancer: A Case-Control Study.
    Gallotta V; Petrillo M; Conte C; Vizzielli G; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Carbone V; Scambia G
    J Minim Invasive Gynecol; 2016; 23(5):769-74. PubMed ID: 26995493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. En-bloc pelvic resection with concomitant rectosigmoid colectomy and immediate anastomosis as part of primary cytoreductive surgery for patients with advanced ovarian cancer.
    Yildirim Y; Ertas IE; Nayki U; Ulug P; Nayki C; Yilmaz I; Gultekin E; Dogan A; Aykas A; Ulug S; Ozdemir A; Solmaz U
    Eur J Gynaecol Oncol; 2014; 35(4):400-7. PubMed ID: 25118481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
    Vogel TJ; Goodman MT; Li AJ; Jeon CY
    Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
    Tseng JH; Cowan RA; Afonso AM; Zhou Q; Iasonos A; Ali N; Thompson E; Sonoda Y; O'Cearbhaill RE; Chi DS; Abu-Rustum NR; Long Roche K
    Gynecol Oncol; 2018 Nov; 151(2):287-293. PubMed ID: 30185381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed?
    Klein DA; Mann AK; Freeman AH; Liao CI; Kapp DS; Chan JK
    Am J Obstet Gynecol; 2020 Feb; 222(2):170.e1-170.e11. PubMed ID: 31421122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of beta blockers on epithelial ovarian cancer survival.
    Diaz ES; Karlan BY; Li AJ
    Gynecol Oncol; 2012 Nov; 127(2):375-8. PubMed ID: 22819786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women.
    Chishti U; Aziz AB
    J Pak Med Assoc; 2015 Mar; 65(3):306-9. PubMed ID: 25933567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
    Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
    J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
    Garcia-Soto AE; Java JJ; Nieves Neira W; Pearson JM; Cohn DE; Lele SB; Tewari KS; Walker JL; Alvarez Secord A; Armstrong DK; Copeland LJ
    Gynecol Oncol; 2016 Dec; 143(3):484-489. PubMed ID: 27726923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Birth weight and the risk of histological subtypes of ovarian and endometrial cancers: Results from the Copenhagen School Health Records Register.
    Trabert B; Aarestrup J; Ulrich LG; Wentzensen N; Sørensen TIA; Baker JL
    Gynecol Oncol; 2018 Mar; 148(3):547-552. PubMed ID: 29331371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of palliative care referral in ovarian cancer: A single institution 5 year retrospective analysis.
    Nitecki R; Diver EJ; Kamdar MM; Boruta DM; Del Carmen MC; Clark RM; Goodman A; Schorge JO; Growdon WB
    Gynecol Oncol; 2018 Mar; 148(3):521-526. PubMed ID: 29395315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.